retatrutide peptide clinical trial results Phase 3: TRIUMPH Program 2026 Retatrutide Results: 24% Weight Loss

All methods were performed in accordance with the relevant guidelines

Notably, with a significant 29% risk reduction when looking at three or more years exposure to GLP-1RA. They added, Our sensitivity analysis supported the finding of risk reduction when looking at users of GLP-1RA. These findings support the possibility of GLP-1RA being an adjunctive therapy to IOP-reducing eye drops in glaucoma management, the authors argue

Step-down users and broader weight-management consumers are likely to widen the addressable market over time as the category becomes easier to recognize

Are we doctors or scientists

To update the evidence base, the researchers examined national insurance claims data from 11.7 million adults with a diagnosis of obesity, overweight, and/or diabetes between 2022 and 2024